A road map for prioritizing warheads for cysteine targeting covalent inhibitors

Péter Ábrányi-Balogh, László Petri, T. Imre, Péter Szijj, Andrea Scarpino, Martina Hrast, Ana Mitrović, Urša Pečar Fonovič, Krisztina Németh, Hélène Barreteau, David I. Roper, Kata Horváti, G. Ferenczy, Janko Kos, Janez Ilaš, Stanislav Gobec, György M. Keserű

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Targeted covalent inhibitors have become an integral part of a number of therapeutic protocols and are the subject of intense research. The mechanism of action of these compounds involves the formation of a covalent bond with protein nucleophiles, mostly cysteines. Given the abundance of cysteines in the proteome, the specificity of the covalent inhibitors is of utmost importance and requires careful optimization of the applied warheads. In most of the cysteine targeting covalent inhibitor programs the design strategy involves incorporating Michael acceptors into a ligand that is already known to bind non-covalently. In contrast, we suggest that the reactive warhead itself should be tailored to the reactivity of the specific cysteine being targeted, and we describe a strategy to achieve this goal. Here, we have extended and systematically explored the available organic chemistry toolbox and characterized a large number of warheads representing different chemistries. We demonstrate that in addition to the common Michael addition, there are other nucleophilic addition, addition-elimination, nucleophilic substitution and oxidation reactions suitable for specific covalent protein modification. Importantly, we reveal that warheads for these chemistries impact the reactivity and specificity of covalent fragments at both protein and proteome levels. By integrating surrogate reactivity and selectivity models and subsequent protein assays, we define a road map to help enable new or largely unexplored covalent chemistries for the optimization of cysteine targeting inhibitors.

Original languageEnglish
Pages (from-to)94-107
Number of pages14
JournalEuropean Journal of Medicinal Chemistry
Volume160
DOIs
Publication statusPublished - Dec 5 2018

Fingerprint

Cysteine
Proteome
Proteins
Organic Chemistry
Nucleophiles
Covalent bonds
Assays
Substitution reactions
Ligands
Oxidation
Research
Therapeutics

Keywords

  • Cathepsin B
  • Cathepsin X
  • Covalent inhibitors
  • Electrophilic warheads
  • GSH reactivity assay
  • MurA
  • Oligopeptide specificity assay

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

A road map for prioritizing warheads for cysteine targeting covalent inhibitors. / Ábrányi-Balogh, Péter; Petri, László; Imre, T.; Szijj, Péter; Scarpino, Andrea; Hrast, Martina; Mitrović, Ana; Fonovič, Urša Pečar; Németh, Krisztina; Barreteau, Hélène; Roper, David I.; Horváti, Kata; Ferenczy, G.; Kos, Janko; Ilaš, Janez; Gobec, Stanislav; Keserű, György M.

In: European Journal of Medicinal Chemistry, Vol. 160, 05.12.2018, p. 94-107.

Research output: Contribution to journalArticle

Ábrányi-Balogh, P, Petri, L, Imre, T, Szijj, P, Scarpino, A, Hrast, M, Mitrović, A, Fonovič, UP, Németh, K, Barreteau, H, Roper, DI, Horváti, K, Ferenczy, G, Kos, J, Ilaš, J, Gobec, S & Keserű, GM 2018, 'A road map for prioritizing warheads for cysteine targeting covalent inhibitors', European Journal of Medicinal Chemistry, vol. 160, pp. 94-107. https://doi.org/10.1016/j.ejmech.2018.10.010
Ábrányi-Balogh, Péter ; Petri, László ; Imre, T. ; Szijj, Péter ; Scarpino, Andrea ; Hrast, Martina ; Mitrović, Ana ; Fonovič, Urša Pečar ; Németh, Krisztina ; Barreteau, Hélène ; Roper, David I. ; Horváti, Kata ; Ferenczy, G. ; Kos, Janko ; Ilaš, Janez ; Gobec, Stanislav ; Keserű, György M. / A road map for prioritizing warheads for cysteine targeting covalent inhibitors. In: European Journal of Medicinal Chemistry. 2018 ; Vol. 160. pp. 94-107.
@article{01ea4bf5c1634401870b631d68c7743b,
title = "A road map for prioritizing warheads for cysteine targeting covalent inhibitors",
abstract = "Targeted covalent inhibitors have become an integral part of a number of therapeutic protocols and are the subject of intense research. The mechanism of action of these compounds involves the formation of a covalent bond with protein nucleophiles, mostly cysteines. Given the abundance of cysteines in the proteome, the specificity of the covalent inhibitors is of utmost importance and requires careful optimization of the applied warheads. In most of the cysteine targeting covalent inhibitor programs the design strategy involves incorporating Michael acceptors into a ligand that is already known to bind non-covalently. In contrast, we suggest that the reactive warhead itself should be tailored to the reactivity of the specific cysteine being targeted, and we describe a strategy to achieve this goal. Here, we have extended and systematically explored the available organic chemistry toolbox and characterized a large number of warheads representing different chemistries. We demonstrate that in addition to the common Michael addition, there are other nucleophilic addition, addition-elimination, nucleophilic substitution and oxidation reactions suitable for specific covalent protein modification. Importantly, we reveal that warheads for these chemistries impact the reactivity and specificity of covalent fragments at both protein and proteome levels. By integrating surrogate reactivity and selectivity models and subsequent protein assays, we define a road map to help enable new or largely unexplored covalent chemistries for the optimization of cysteine targeting inhibitors.",
keywords = "Cathepsin B, Cathepsin X, Covalent inhibitors, Electrophilic warheads, GSH reactivity assay, MurA, Oligopeptide specificity assay",
author = "P{\'e}ter {\'A}br{\'a}nyi-Balogh and L{\'a}szl{\'o} Petri and T. Imre and P{\'e}ter Szijj and Andrea Scarpino and Martina Hrast and Ana Mitrović and Fonovič, {Urša Pečar} and Krisztina N{\'e}meth and H{\'e}l{\`e}ne Barreteau and Roper, {David I.} and Kata Horv{\'a}ti and G. Ferenczy and Janko Kos and Janez Ilaš and Stanislav Gobec and Keserű, {Gy{\"o}rgy M.}",
year = "2018",
month = "12",
day = "5",
doi = "10.1016/j.ejmech.2018.10.010",
language = "English",
volume = "160",
pages = "94--107",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - A road map for prioritizing warheads for cysteine targeting covalent inhibitors

AU - Ábrányi-Balogh, Péter

AU - Petri, László

AU - Imre, T.

AU - Szijj, Péter

AU - Scarpino, Andrea

AU - Hrast, Martina

AU - Mitrović, Ana

AU - Fonovič, Urša Pečar

AU - Németh, Krisztina

AU - Barreteau, Hélène

AU - Roper, David I.

AU - Horváti, Kata

AU - Ferenczy, G.

AU - Kos, Janko

AU - Ilaš, Janez

AU - Gobec, Stanislav

AU - Keserű, György M.

PY - 2018/12/5

Y1 - 2018/12/5

N2 - Targeted covalent inhibitors have become an integral part of a number of therapeutic protocols and are the subject of intense research. The mechanism of action of these compounds involves the formation of a covalent bond with protein nucleophiles, mostly cysteines. Given the abundance of cysteines in the proteome, the specificity of the covalent inhibitors is of utmost importance and requires careful optimization of the applied warheads. In most of the cysteine targeting covalent inhibitor programs the design strategy involves incorporating Michael acceptors into a ligand that is already known to bind non-covalently. In contrast, we suggest that the reactive warhead itself should be tailored to the reactivity of the specific cysteine being targeted, and we describe a strategy to achieve this goal. Here, we have extended and systematically explored the available organic chemistry toolbox and characterized a large number of warheads representing different chemistries. We demonstrate that in addition to the common Michael addition, there are other nucleophilic addition, addition-elimination, nucleophilic substitution and oxidation reactions suitable for specific covalent protein modification. Importantly, we reveal that warheads for these chemistries impact the reactivity and specificity of covalent fragments at both protein and proteome levels. By integrating surrogate reactivity and selectivity models and subsequent protein assays, we define a road map to help enable new or largely unexplored covalent chemistries for the optimization of cysteine targeting inhibitors.

AB - Targeted covalent inhibitors have become an integral part of a number of therapeutic protocols and are the subject of intense research. The mechanism of action of these compounds involves the formation of a covalent bond with protein nucleophiles, mostly cysteines. Given the abundance of cysteines in the proteome, the specificity of the covalent inhibitors is of utmost importance and requires careful optimization of the applied warheads. In most of the cysteine targeting covalent inhibitor programs the design strategy involves incorporating Michael acceptors into a ligand that is already known to bind non-covalently. In contrast, we suggest that the reactive warhead itself should be tailored to the reactivity of the specific cysteine being targeted, and we describe a strategy to achieve this goal. Here, we have extended and systematically explored the available organic chemistry toolbox and characterized a large number of warheads representing different chemistries. We demonstrate that in addition to the common Michael addition, there are other nucleophilic addition, addition-elimination, nucleophilic substitution and oxidation reactions suitable for specific covalent protein modification. Importantly, we reveal that warheads for these chemistries impact the reactivity and specificity of covalent fragments at both protein and proteome levels. By integrating surrogate reactivity and selectivity models and subsequent protein assays, we define a road map to help enable new or largely unexplored covalent chemistries for the optimization of cysteine targeting inhibitors.

KW - Cathepsin B

KW - Cathepsin X

KW - Covalent inhibitors

KW - Electrophilic warheads

KW - GSH reactivity assay

KW - MurA

KW - Oligopeptide specificity assay

UR - http://www.scopus.com/inward/record.url?scp=85054770415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054770415&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2018.10.010

DO - 10.1016/j.ejmech.2018.10.010

M3 - Article

VL - 160

SP - 94

EP - 107

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -